Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
eprx · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$19.00
Consensus
$19.00
+214.8% upside
Low
$19.00
Median: $19 · Last Close: $6.04
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.73 | ↓ 5.00% |
1-day model range: $5.69–$5.78. Peak: $5.78 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $6 | +1.1% |
| 2028 | $6 | +1.6% |
| 2029 | $6 | +1.9% |
| 2030 | $6 | +2.1% |
| 2031 | — | +2.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · EPRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-15 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2026-01-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Eupraxia Pharmaceuticals Inc. (EPRX) stock. Of the recent 6 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover EPRX.
Analyst Recommendation Trends
EPRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$21M
EPS This Year
$-1.17
EPS Next Year
$-1.18
↑ 1.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast EPRX EPS of $-1.17 for the current fiscal year, based on estimates from 7 analysts. The EPRX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The EPRX stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus EPRX price target is $19.00 (+214.8% upside), with an analyst consensus of Buy.
The EPRX short-term stock prediction for tomorrow is $5.73 (-5.00%). The EPRX stock price prediction for 2027 estimates an average of $6. The EPRX stock prediction for 2030 projects a range of $6–$7.
Eupraxia Pharmaceuticals Inc. trades on NASDAQ under the ticker EPRX. The EPRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
EPRX forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month EPRX price target is $19.00, with a high forecast of $19.00 and a low of $19.00. The median price target is shown in the chart above when available. This implies +214.8% potential upside from the current price of $6.04.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.